Key result
Myocet, a liposomal formulation of doxorubicin, offers a significantly improved therapeutic index with less cardiotoxicity and equal efficacy compared to conventional doxorubicin in breast cancer.
Why the study?
Does liposome-encapsulated doxorubicin citrate reduce cardiotoxicity compared to conventional doxorubicin in patients with metastatic breast cancer?
Population
Patients with metastatic breast cancer
Comparison
Liposome-encapsulated doxorubicin citrate vs Conventional doxorubicin
Design
Review
Authors
Loading...
Myocet may reduce cardiotoxicity risk in metastatic breast cancer; leaves open confirmation versus conventional doxorubicin in randomized trials.
Does liposome-encapsulated doxorubicin citrate reduce cardiotoxicity compared to conventional doxorubicin in patients with metastatic breast cancer?
Liposome-encapsulated doxorubicin provides an equally efficacious but less cardiotoxic alternative to conventional doxorubicin, reducing the risk of congestive heart failure in breast cancer therapy.
Batist et al. (2002) conducted a review in metastatic breast cancer. Myocet (liposomal formulation of doxorubicin) vs. conventional doxorubicin was evaluated. Myocet, a liposomal formulation of doxorubicin, offers a significantly improved therapeutic index with less cardiotoxicity and equal efficacy compared to conventional doxorubicin in breast cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: